Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797959 | 0.84 | RAB9A (0.56) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL7336243 | 0.80 | MAPT (0.63) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL3798973 | 0.78 | NPC1 (0.45) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL31276277 | 0.78 | MAPT (0.78) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL1748040 | 0.78 | MAPT (0.78) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL31430627 | 0.77 | NPC1 (0.56) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL31276462 | 0.77 | MAPT (0.70) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL2621291 | 0.77 | MAPT (0.70) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL6902568 | 0.76 | NPC1 (0.63) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL18901151 | 0.76 | NPC1 (0.63) | RAB9ANPC1MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157085-B1 | Oxazole, derivatives of tetracyclines | WYETH LLC (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2157085-A1 | Oxazole, derivatives of tetracyclines | Wyeth a Corporation of the State of Delaware (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1692117-B1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | WYETH CORP (US) | 2009-09-30 | — | — | EP | disclosed |
| US-20080177080-A1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | WYETH (US) | 2008-07-24 | — | — | US | disclosed |
| US-7365087-B2 | Oxazole derivatives of tetracyclines | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080064667-A1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | WYETH (US) | 2008-03-13 | — | — | US | disclosed |
| US-7176225-B2 | Oxazole derivatives of tetracyclines | WYETH (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1692117-A1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050153944-A1 | For example, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide; useful against antibiotic resistant organisms | WYETH (US) | 2005-07-14 | — | — | US | disclosed |
| WO-2005056538-A1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | WYETH (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064667-A1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | OXA1L, CXXC5, TET3 | RAB9A 3758/4885NPC1 4513/4885MAPT 2552/4885 |
| US-20050153944-A1 | For example, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide; useful against antibiotic resistant organisms | DHRS9, SPOUT1, DAO | RAB9A 1055/4885NPC1 3424/4885MAPT 4545/4885 |
| US-20080177080-A1 | OXAZOLE DERIVATIVES OF TETRACYCLINES | OXA1L, CXXC5, TET3 | RAB9A 3758/4885NPC1 4513/4885MAPT 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.